163 related articles for article (PubMed ID: 29609548)
21. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children.
Mungall BA; Hoet B; Nieto Guevara J; Soumahoro L
Expert Rev Vaccines; 2022 Feb; 21(2):201-214. PubMed ID: 34882050
[TBL] [Abstract][Full Text] [Related]
22. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
[TBL] [Abstract][Full Text] [Related]
23. Pneumococcal carriage in vaccine-eligible children and unvaccinated infants in Lao PDR two years following the introduction of the 13-valent pneumococcal conjugate vaccine.
Satzke C; Dunne EM; Choummanivong M; Ortika BD; Neal EFG; Pell CL; Nation ML; Fox KK; Nguyen CD; Gould KA; Hinds J; Chanthongthip A; Xeuatvongsa A; Mulholland EK; Sychareun V; Russell FM
Vaccine; 2019 Jan; 37(2):296-305. PubMed ID: 30502068
[TBL] [Abstract][Full Text] [Related]
24. Indirect effects of 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in children hospitalised with acute respiratory infection despite heterogeneous vaccine coverage: an observational study in Lao People's Democratic Republic.
Chan J; Lai JYR; Nguyen CD; Vilivong K; Dunne EM; Dubot-Pérès A; Fox K; Hinds J; Moore KA; Nation ML; Pell CL; Xeuatvongsa A; Vongsouvath M; Newton PN; Mulholland K; Satzke C; Dance DAB; Russell FM;
BMJ Glob Health; 2021 Jun; 6(6):. PubMed ID: 34108146
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study.
Domingues CM; Verani JR; Montenegro Renoiner EI; de Cunto Brandileone MC; Flannery B; de Oliveira LH; Santos JB; de Moraes JC;
Lancet Respir Med; 2014 Jun; 2(6):464-71. PubMed ID: 24726406
[TBL] [Abstract][Full Text] [Related]
26. Impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in children under 5 years of age in the Czech Republic.
Kozakova J; Krizova P; Maly M
PLoS One; 2021; 16(2):e0247862. PubMed ID: 33635933
[TBL] [Abstract][Full Text] [Related]
27. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.
Regev-Yochay G; Katzir M; Strahilevitz J; Rahav G; Finn T; Miron D; Maor Y; Chazan B; Schindler Y; Dagan R;
Vaccine; 2017 Apr; 35(18):2449-2456. PubMed ID: 28342668
[TBL] [Abstract][Full Text] [Related]
28. Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010-2013.
Martinelli D; Pedalino B; Cappelli MG; Caputi G; Sallustio A; Fortunato F; Tafuri S; Cozza V; Germinario C; Chironna M; Prato R;
Hum Vaccin Immunother; 2014; 10(1):33-9. PubMed ID: 24096297
[TBL] [Abstract][Full Text] [Related]
29. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T
Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483
[TBL] [Abstract][Full Text] [Related]
30. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.
Miller E; Andrews NJ; Waight PA; Slack MP; George RC
Vaccine; 2011 Nov; 29(49):9127-31. PubMed ID: 21983361
[TBL] [Abstract][Full Text] [Related]
32. Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance.
; Mackenzie GA; Hill PC; Jeffries DJ; Ndiaye M; Sahito SM; Hossain I; Uchendu U; Ameh D; Adeyemi O; Pathirana J; Olatunji Y; Abatan B; Muhammad BS; Ahameefula E; Fombah AE; Adeshola B; Lobga BG; Saha D; Mackenzie R; Odutola A; Plumb ID; Akano A; Ebruke BE; Ideh RC; Kuti B; Githua P; Olutunde E; Ofordile O; Green E; Usuf E; Badji H; Ikumapayi UN; Manjang A; Salaudeen R; Nsekpong ED; Jarju S; Antonio M; Sambou S; Ceesay L; Lowe-Jallow Y; Fofana S; Jasseh M; Mulholland K; Knoll M; Levine OS; Howie SR; Adegbola RA; Greenwood BM; Corrah T
Lancet Infect Dis; 2021 Sep; 21(9):1293-1302. PubMed ID: 34280357
[TBL] [Abstract][Full Text] [Related]
33. Vaccine effectiveness of PCV13 in a 3+1 vaccination schedule.
Weinberger R; van der Linden M; Imöhl M; von Kries R
Vaccine; 2016 Apr; 34(18):2062-5. PubMed ID: 26920471
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of the 7-valent pneumococcal conjugate vaccine against vaccine-type invasive disease among children in Uruguay: an evaluation using existing data.
Picón T; Alonso L; García Gabarrot G; Speranza N; Casas M; Arrieta F; Camou T; Rosa R; De Oliveira LH; Verani JR
Vaccine; 2013 Jul; 31 Suppl 3():C109-13. PubMed ID: 23777683
[TBL] [Abstract][Full Text] [Related]
35. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case-control study.
Guevara M; Barricarte A; Torroba L; Herranz M; Gil-Setas A; Gil F; Bernaola E; Ezpeleta C; Castilla J;
Euro Surveill; 2016; 21(14):. PubMed ID: 27103428
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of the 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-Serotype Otitis Media.
Dagan R; Van Der Beek BA; Ben-Shimol S; Pilishvili T; Givon-Lavi N
Clin Infect Dis; 2021 Aug; 73(4):650-658. PubMed ID: 33507250
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
[TBL] [Abstract][Full Text] [Related]
38. Pneumococcal carriage in children in Ulaanbaatar, Mongolia before and one year after the introduction of the 13-valent pneumococcal conjugate vaccine.
von Mollendorf C; Dunne EM; La Vincente S; Ulziibayar M; Suuri B; Luvsantseren D; Narangerel D; Ortika BD; Pell CL; Nation ML; Alamrousi A; Hinds J; Demberelsuren S; Nguyen C; Mungun T; Mulholland EK; Satzke C
Vaccine; 2019 Jul; 37(30):4068-4075. PubMed ID: 31174939
[TBL] [Abstract][Full Text] [Related]
39. Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance.
Ben-Shimol S; Regev-Yochay G; Givon-Lavi N; van der Beek BA; Brosh-Nissimov T; Peretz A; Megged O; Dagan R; ;
Clin Infect Dis; 2022 May; 74(9):1639-1649. PubMed ID: 34293091
[TBL] [Abstract][Full Text] [Related]
40. Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
Hu T; Song Y; Done N; Liu Q; Sarpong EM; Lemus-Wirtz E; Signorovitch J; Mohanty S; Weiss T
BMC Public Health; 2022 Sep; 22(1):1677. PubMed ID: 36064378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
